115 related articles for article (PubMed ID: 24567353)
21. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
[TBL] [Abstract][Full Text] [Related]
22. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
24. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Harada K; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Vakar-Lopez F; Minna JD; Sagalowsky A; Czerniak B; Gazdar AF
Cancer Res; 2001 Dec; 61(24):8659-63. PubMed ID: 11751381
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages.
Beukers W; Hercegovac A; Vermeij M; Kandimalla R; Blok AC; van der Aa MM; Zwarthoff EC; Zuiverloon TC
J Urol; 2013 Jul; 190(1):311-6. PubMed ID: 23369722
[TBL] [Abstract][Full Text] [Related]
26. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
Lin YL; Wang YP; Li HZ; Zhang X
Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
[TBL] [Abstract][Full Text] [Related]
27. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma.
Xiong G; Liu J; Tang Q; Fan Y; Fang D; Yang K; Xie F; Zhang M; Zhang L; Liu L; Zhang C; Yao L; Yang L; Ci W; Zhao W; Gong Y; He Q; Gong K; He Z; Wang G; Li X; Guo Y; Zhou L
Epigenomics; 2015 Aug; 7(5):733-44. PubMed ID: 25912368
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases.
Amasyali AS; Kucukgergin C; Erdem S; Sanli O; Seckin S; Nane I
J Urol; 2012 Dec; 188(6):2398-403. PubMed ID: 23088972
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M; Gaisa NT; Antony P; Fiedler D; Heidenreich A; Otto W; Denzinger S; Bertz S; Hartmann A; Karl A; Knüchel R; Dahl E
Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation markers and early recurrence in stage I lung cancer.
Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
[TBL] [Abstract][Full Text] [Related]
34. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
[TBL] [Abstract][Full Text] [Related]
35. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
Pignot G; Bieche I; Vacher S; Güet C; Vieillefond A; Debré B; Lidereau R; Amsellem-Ouazana D
Eur Urol; 2009 Oct; 56(4):678-88. PubMed ID: 18513850
[TBL] [Abstract][Full Text] [Related]
36. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation.
Byzia E; Soloch N; Bodnar M; Szaumkessel M; Kiwerska K; Kostrzewska-Poczekaj M; Jarmuz-Szymczak M; Szylberg L; Wierzbicka M; Bartochowska A; Kalinowicz E; Grenman R; Szyfter K; Marszalek A; Giefing M
Mol Carcinog; 2018 Jul; 57(7):878-885. PubMed ID: 29566279
[TBL] [Abstract][Full Text] [Related]
37. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
38. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
39. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
